Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097555 | 0.80 | HDAC3 (0.64) | KMT2APOLBMEN1MAPTLMNA | |
| SCHEMBL2098191 | 0.79 | NPC1 (0.63) | L3MBTL1KDM4EMAPTLMNAHDAC3 | |
| SCHEMBL14468583 | 0.77 | KMT2A (1.00) | KMT2APOLBMEN1L3MBTL1KDM4E | |
| SCHEMBL1754877 | 0.77 | POLB (0.65) | KMT2APOLBMEN1L3MBTL1KDM4E | |
| SCHEMBL2097478 | 0.77 | ALDH1A1 (0.66) | KMT2AL3MBTL1MAPTTSHR | |
| SCHEMBL4003605 | 0.76 | KMT2A (0.71) | KMT2APOLBMEN1L3MBTL1KDM4E | |
| SCHEMBL89061 | 0.75 | KMT2A (0.56) | KMT2APOLBMEN1L3MBTL1KDM4E | |
| SCHEMBL2097381 | 0.75 | BCHE (0.46) | POLBL3MBTL1TDP1MTNR1BHDAC3 | |
| SCHEMBL7368190 | 0.74 | HDAC1 (0.60) | KMT2APOLBMEN1L3MBTL1KDM4E | |
| SCHEMBL90352 | 0.74 | KMT2A (0.55) | KMT2APOLBMEN1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| EP-1831153-A2 | COMPOUNDS DERIVED FROM LIDOCAINE, PHARMACEUTICAL COMPOSITIONS, USE AND METHOD OF TREATMENT, PREVENTION OR INHIBITION OF DISEASES | FUNDA AO OSWALDO CRUZ-FIOCRUZ (BR) | 2007-09-12 | — | — | EP | claimed |
| WO-2005120148-A2 | COMPOUNDS DERIVED FROM LIDOCAINE, PHARMACEUTICAL COMPOSITIONS, USE AND METHOD OF TREATMENT, PREVENTION OR INHIBITION OF DISEASES | FUNDAÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2005-12-22 | — | — | WO | claimed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | KMT2A 3557/4885POLB 2684/4885MEN1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.